Articles tagged with Solid Tumors
Researchers at Columbia University have engineered tumor-colonizing bacteria to produce synthetic targets that direct CAR-T cells to destroy cancer cells. The probiotic-guided CAR-T cell platform has shown safety and effectiveness in multiple models of human and mouse cancers.
Researchers developed a nanocapsule that reduces lactate levels and releases hydrogen peroxide, recruiting and activating immune cells to attack tumors. The approach increased immune cell activity by 2-5-fold, improving cancer immunotherapy success rates.
Researchers have identified a neoplastic fusion transcript RAD51AP1-DYRK4 in luminal B breast cancer, associated with higher ki67 expression and aggressive clinical characteristics. MEK inhibitor trametinib may be effective in blocking the MEK-ERK signaling driven by this fusion.
A first-in-human study demonstrates the efficacy of a novel PRMT5 inhibitor, JNJ-64619178, in treating advanced solid tumors. The treatment showed manageable dose-dependent toxicity and achieved preliminary antitumor activity in patients with various cancer types.
A novel biomaterials-based approach enhances adoptive T cell therapy with cancer vaccine technology, providing strong and long-lasting effects against solid tumors. In mice carrying melanomas, SIVET enables fast tumor shrinking and long-term protection.
Researchers at the University of Pennsylvania School of Engineering and Applied Science have developed a new therapy that uses engineered macrophages to eliminate solid tumors. The treatment works by silencing a molecular pathway that prevents white blood cells from attacking cancer cells, allowing them to recognize and destroy tumoroids.
Analysis of rare cancer patients treated with checkpoint inhibitors reveals a linear correlation between tumor shrinkage and patient survival, contradicting earlier threshold-based models. The study suggests that using partial- or complete-response rates may miss signals of longer survival.
Researchers have found a compound that can prevent cisplatin-induced renal toxicity and improve the outcomes of cancer treatment. The aromatic ketone 2',4',6'-trihydroxyacetophenone (THA) inhibits the CCBL1-mediated metabolism of cisplatin, reducing its toxic effects without affecting its potency.
Researchers discovered that FDA-approved HDAC-inhibitors can impact energy metabolism in solid tumor cells, including glioblastoma. The combination of HDAC-inhibitors and imipridones may synergize to enhance killing of GBM cells by reversing cellular respiration.
University of Pittsburgh researchers created a universal receptor system allowing T cells to recognize any cell surface target. This enables highly customizable CAR T cell and other immunotherapies for treating cancer and diseases, with potential applications in solid tumors.
Researchers have developed a new immunotherapy targeting tumour macrophages, which are immunosuppressive cells that weaken the immune system. The treatment, RImAb, reduces tumour growth and modifies the tumour microenvironment, offering potential for a new line of treatment for lung cancer patients.
A new study has shown that FAPI PET imaging is superior to standard FDG PET in evaluating multiple types of cancer. A newly designed FAP-targeted treatment also suppressed tumor growth in several common cancers, suggesting a powerful tool for the field of clinical nuclear medicine.
Researchers found that necroptosis promotes metastasis in breast cancer models, and blocking it leads to inhibition of metastasis. Necroptosis may be a key factor in tumor progression, and targeting its regulators could be critical for mitigating metastasis.
Researchers found a partial response in a patient with pancreatic acinar cell carcinoma, as well as stable disease in 11 patients, when combining riluzole with sorafenib in a phase I trial. The combination was safe and tolerable, and further exploration of its potential is warranted.
Researchers identified high expression of glypican-1 in primary solid tumors, correlating with poor prognosis in various cancer types. Suppression of GPC1 attenuated cancer cell proliferation, suggesting its potential as a novel diagnostic tool and target for therapy.
Researchers discovered that targeting two inflammatory regulators simultaneously can boost T cell expansion and increase antitumor immune activity in models. The findings showed at least 10 times greater T cell expansion when both regulators were knocked out, resulting in improved durability.
The study validated the clinical utility of Strata Oncology's proprietary pan-solid tumor predictive biomarker, Immunotherapy Response Score (IRS), which predicts response to checkpoint inhibitor therapy. IRS captures tumor biology and microenvironment by combining tumor mutation burden with quantitative expression of PD-L1, PD-1, ADAM...
Researchers found that primary cancer tumors have a sluggish conversion of nutrients to usable cellular energy, conserving energy for growth and metastasis. The discovery has vast implications for anti-cancer strategies, directing attention to slow energy metabolism.
Researchers have discovered that inhibiting conventional signalling pathway by disrupting LCK allows more efficient tumour cell killing, using FYN protein instead. This approach enhances T-cell function and reduces graft-versus-host disease, making CAR-T therapy more accessible to patients.
A preclinical study shows CAR T cell therapy can eliminate residual tumor cells after surgery in mice with breast and pancreatic cancer. The treatment involves applying a gel containing human CAR T cells to surgical wounds, allowing the mice to survive where they would otherwise succumb to tumor recurrence.
A new method utilizes an unnatural sugar to anchor cytokines to T cells, enhancing their functions without systemic side-effects. The approach has shown promise in stimulating the host immune system against tumor cells and inhibiting tumor growth in mice with melanoma.
Researchers at Integral Molecular have developed highly specific antibodies against Claudin 6, a tumor-specific protein found in multiple solid tumors. The antibodies use a single atomic contact point to derive exquisite specificity, allowing them to target cancer cells while avoiding healthy tissues.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
Researchers have developed a new therapy that uses CAR T cells to target macrophages in tumors, reducing their growth and increasing anti-tumor immunity. The treatment was shown to be effective in preclinical models of ovarian, lung, and pancreatic cancers.
A new epigenetics drug, tazemetostat, has been found to stop bladder cancer growth by activating the immune system, not just inhibiting tumors. The drug targets the EZH2 gene and is being tested in clinical trials for late-stage bladder cancer.
A phase 3 study shows that tumour-infiltrating lymphocytes (TIL) therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma. The treatment reduces disease progression or death by 50% in patients treated with TILs.
A combination of immunotherapy and virotherapy using myxoma virus provides new hope for patients with treatment resistant cancers. The approach boosts the immune capacity to effectively target and destroy cancer cells, inducing a form of cell death called autosis.
Researchers found that Merkel cell carcinoma (MCC) Glypican-3 (GPC3) is expressed in nearly 70% of MCC tumors and up to 90% of MCPyV-negative cases. GPC3 expression is associated with worse prognosis, including increased risk of death from MCC. This makes GPC3 a promising target for chimeric antigen receptor T cell therapy.
Researchers developed a small molecule that effectively controls tumor growth by inhibiting PD-1/PD-L1 binding, overcoming accessibility and cost issues of existing antibody treatments. The new molecule has advantages in terms of affordability and oral administration, making immunotherapy more accessible to all cancer patients.
Researchers used a new 3D imaging technique to analyze the interaction between T-cell therapies and solid mini-tumors, revealing a wide variety of behaviors in engineered T cells. The study identified specific gene signatures of highly potent T cells that can target multiple tumor cells.
Researchers discovered that targeting the protein complex cBAF can increase memory T-cell generation, leading to improved CAR-T cell efficacy against solid tumors. By understanding the early decision points in T-cell activation, scientists can create more effective cancer therapies.
A screening tool developed at the University of Strathclyde has increased the number of tests on solid tumour samples by up to 50 times. The technology enables large-scale testing of immunotherapies like CAR-T cell therapy, which is effective against many haematological cancers but faces challenges when treating solid tumours.
A world-class team led by Dr. Catherine Bollard aims to develop novel immunotherapy treatments for children with solid cancers, aiming to improve survival and diminish lifelong toxicities. The team will receive $25m funding to tackle the challenging issue of solid tumors in children.
Researchers developed a novel nanoparticle to deliver ARL67156, an enzyme inhibitor that prevents ATP degradation into adenosine, selectively targeting solid tumors. The treatment substantially suppressed tumor growth and resulted in prolonged survival in mouse models.
A newly developed small-molecular radiopharmaceutical pair has successfully visualized and treated melanoma in a preclinical study. The theranostic approach targets metabotropic glutamate receptor 1 (GRM1) found in many human solid tumors.
Researchers found that combining chemotherapy with immunotherapy increased one-year survival rates for patients with advanced pancreatic cancer, with anti-PD-1/chemo regimen showing the highest response. The study identified key immune system biomarkers associated with better outcomes, offering new hope for precision oncology.
A study by Cedars-Sinai researchers confirms that counting metastatic lymph nodes is a dominant predictor of cancer death, improving staging and treatment for solid tumors. The simple process can be applied in virtually all medical settings without increased cost or complexity.
Researchers at USC have developed an innovative treatment for prostate cancer, known as synthetic immune receptor (SIR-T) therapy, which has shown promising results in preclinical studies. The new technology was adapted from CAR-T therapy and aims to revolutionize the treatment of not only prostate cancer but also other cancers.
Researchers are developing a novel MRI nanotechnology that targets specific markers in solid tumours, including high-grade brain cancers. The new imaging technology has shown promising preclinical results and is set to be tested in a first-in-human clinical trial.
Researchers developed nanoparticles with a changeable net charge that facilitates intratumor accumulation and penetration, achieving 32.1% of injected dose/g of tissue. This study suggests using the changeable net charge as a promising strategy for tumor-targeted delivery based on the EPR effect.
Researchers developed a digital subtraction technique to identify viral DNA in tumor samples, achieving comparable results to standard clinical methods. The study discovered novel associations between specific tumors and viruses, warranting further investigation.
Researchers from IRB Barcelona and Merus have discovered MCLA-158, a bi-specific antibody targeting cancer stem cells. The treatment prevents metastasis and slows primary tumor growth in experimental models of cancer.
Researchers at Case Western Reserve University discovered that altering macrophage metabolism influences their relationship with T cells, suppressing tumor growth and reducing overall tumor size. The study found PERK protein's involvement in key metabolic pathways and identified a potential clinical drug inhibitor to target it.
A new CAR T-cell product targeting CLDN6 showed acceptable safety and early signs of efficacy in a phase I/II clinical trial. The therapy combined with an mRNA vaccine expanded transferred CAR T cells and improved tumor cell killing.
Researchers at Cincinnati Children's Hospital Medical Center have identified a protein crucial to AML cell survival and found a small molecule that blocks its function, killing cancer cells in lab dishes and mouse models. This potential breakthrough could lead to novel therapies for AML and other conditions.
The first-in-human trial of CAR-M cell therapy demonstrated that engineered macrophages can target and alter the solid tumor microenvironment, altering the composition of myeloid cells and T-cells. This innovative immunotherapy offers a promising new strategy in the fight against cancer.
The study investigated the antibody response to 2 or 3 doses of the BioNTech-Pfizer vaccine in patients with solid tumors treated with anticancer agents. The researchers found that higher antibody levels were associated with better immune response and reduced risk of severe COVID-19.
A recent study published in JNCCN found that 33 out of 81 studies lacked transparency on censoring, which can introduce bias and affect trial results. The researchers emphasize the need for improved transparency and reporting in clinical trials to ensure patients and clinicians make informed decisions.
Researchers create a porous microneedle to deliver CAR T cells into solid tumors, improving anti-tumor effects. The strategy showed enhanced tumor infiltration and amplification of CAR T cells in melanoma models.
Researchers at the University of Alabama at Birmingham have developed a method to identify non-responding tumors using hypoxia imaging, which shows promise for improving response rates. Investigational new drug evofosfamide was found beneficial in treating hypoxic tumors with immunotherapy.
ImCheck's ICT01 selectively activates Vγ9Vδ2 T cells through all three isoforms of BTN3A, overcoming prior limitations. The therapy demonstrates anti-tumor activity in solid and hematologic cancer models.
Researchers have discovered a new drug target for myelodysplastic syndrome (MDS) and other hematologic malignancies, which are sensitive to MEK inhibitors. The study found that mutations affecting RNA splicing alter cells to develop MDS and solid tumors, providing a potential new approach to treating this rare blood cancer.
New targeted therapies are being developed to target genetic alterations in cancer cells, such as the ARID1A mutation found in 10-50% of solid tumours. Early clinical trials suggest that these agents may be effective in treating multiple cancers, including breast, ovarian, and gastric cancer.
Researchers at MD Anderson Cancer Center presented new findings on novel therapeutic approaches, including cell therapy for solid tumors and antibody drug conjugates targeting TROP2. The therapies achieved partial responses in six patients, with an overall response rate of 35.3% and disease control rate of 70.6%.
A new DNA-based test using whole genome sequencing can identify tumour-specific markers to measure cancer levels in children's bodies. This technology has the potential to detect minimal residual disease and change treatment outcomes.
A new study from Penn Medicine demonstrates that RN7SL1, a naturally occurring RNA, can activate the body's own natural T cells to seek out cancer cells that have escaped recognition by CAR T cells. This approach may help improve efforts to treat solid tumors.
Researchers have uncovered a weakness in the key enzyme that solid tumour cancer cells rely on to adapt and survive when oxygen levels are low. Inhibiting this enzyme, called Carbonic Anhydrase IX (CAIX), can effectively stop cancer cell growth.
Researchers at UC San Diego developed a cancer immunotherapy that pairs ultrasound with CAR T-cell therapy to destroy malignant tumors while sparing normal tissue. The therapy significantly slowed down tumor growth in mice and showed minimal on-target, off-tumor side effects.
Researchers have developed a new generation of CAR T cells that safely target and kill solid tumors in mice with mesothelioma, ovarian cancer, and glioblastoma. The 'prime-and-kill' molecular circuits enable specific recognition of tumor antigens on healthy tissues, reducing the risk of side effects.
Researchers at UVA Cancer Center discovered that antibody approaches targeting death receptor-5 could be revived by co-targeting negative biological processes with immune-activating therapy. This combination therapy increased the effectiveness of cancer killer immune cells, shrinking tumors and improving survival in lab mice.